New hope for rare brain cancer: ibrutinib shows promise in relapsed PCNSL
NCT ID NCT05782374
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 25 times
Summary
This study reviews medical records of 36 adults with relapsed or refractory PCNSL, a rare and aggressive brain lymphoma. Researchers want to see how well ibrutinib works alone or combined with R-CHOP chemotherapy. The goal is to measure tumor shrinkage and survival, while checking safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PCNSL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale San Raffaele
Milan, Italy, 20132, Italy
Conditions
Explore the condition pages connected to this study.